Biotech Stock News (RVNC) (DNAI)

Revance Therapeutics (NASDAQ:RVNC) On Tuesday June 14, 2016 shares of Revance Therapeutics went down in after-hours trading by 24% after the company stated that it had failed to meet the primary endpoint of its phase 3 clinical trial. The phase 3 trial was testing patients with lateral catheral lines or Crows Feet. The trial used … Read more

Biotech Stock News (AMGN) (RGLS) (BIIB) (RVNC) (AGN)

Amgen, Inc. (NASDAQ:AMGN) On October 28, 2015 Amgen had announced that it had received FDA approval for its skin cancer drug known as IMLYGIC. This drug is an injection type drug that helps boost the immune system to fight off and kill cancerous skin cells. This therapy only treats Melanoma — skin cancer– but does … Read more

Biotech Stock News (LXRX) (BIOC) (LLY) (AMGN) (AQXP)

Lexicon Pharmaceuticals (NASDAQ:LXRX)¬† On August 3, 2015 shares of Lexicon Pharmaceuticals were up 61% after the company posted positive phase 3 Results in Patients with Carcinoid Syndrome. Carcinoid Syndrome occurs when a carcinoid tumor advances to a later stage. Typically this disease targets the lining of the lungs or stomach of the patient and has … Read more

Biotech Stock News (NYMX) (GALE) (SGYP)

Nymox Pharmaceutical (NASDAQ:NYMX) On July 27, 2015 Nymox surged as high as 100% after the company reported positive phase 3 results for its BPH study. BPH stands for benign prostatic hyperplasia, and is characterized by an enlarged prostate gland. This enlarged prostate gland causes problems such as problems of urinating or the need to urinate … Read more

Biotech Stock News (RXII) (MRK) (BMY) (CNAT) (ICPT)

Rxi Pharmaceuticals Corp (NASDAQ: RXII) Rxi Pharmaceuticals last week on March 23, 2015 presented at the 73rd Annual Academy of Dermatology in which the company reported ¬†positive progress on clinical trial updates for its dermatology programs. The clinical trial with RXI-109-1301 phase 2a enrolled patients to be tested for hypertrophic scars on the abdomen only. … Read more